Proprietary portfolio

We develop superior therapeutics that are clinically derisked and address unmet patient need in high value markets including diabetes and other cardiometabolic diseases, based on our Arestat® technology platform

OUR PORTFOLIO

Partnering

We partner with leading pharmaceutical and medtech companies to develop superior therapeutic profiles, leveraging our innovative and proprietary formulation and drug delivery technology

PARTNERING

Validated technology

Our development expertise is underpinned by our world-leading Arestat® technology platform, protected by a robust intellectual property portfolio

OUR TECHNOLOGY

Latest News

  • 17th August 2026

    HCP Live: Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI

    CLICK HERE
  • 13th August 2026

    Peer-Reviewed Publication of AT278 Study in Diabetes, Obesity and Metabolism journal

    ↓ DOWNLOAD PDF
  • 30th July 2026

    Diabetes, Obesity and Metabolism article – A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

    CLICK HERE